Health Care's Elite Eight Stocks: AstraZeneca vs. AbbVie

Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Wichita State have busted the brackets of would-be basketball prognosticators.

Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own bracket filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament as determined by the collective intelligence of our CAPS community.

This Elite Eight matchup is a heavyweight bout between AstraZeneca and AbbVie. Watch and find out which stock gets eliminated and which will advance to the next round.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

The article Health Care's Elite Eight Stocks: AstraZeneca vs. AbbVie originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.